NIIMBL Receives $153 Million in Awards from NIST
NEWARK, DE. — Today, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) confirms that it has received $153M in new funding from the National Institute of Standards and Technology (NIST) as announced by U.S. Commerce Secretary Gina Raimondo at NIIMBL’s National Meeting in Washington, DC. The two awards include $70M to continue federal funding for NIIMBL for an additional five years and an additional $83M for coronavirus response projects under the American Rescue Plan (ARP).
ARM and NIIMBL Release Project A-Gene
Washington, DC — June 24, 2021
The Alliance for Regenerative Medicine (ARM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) today released Project A-Gene, a multistakeholder collaboration to incorporate Quality by Design (QbD) principles into a manufacturing case study of a viral vector commonly used in gene therapies.
NIIMBL Announces $4.6M to Fund 10 New Biopharmaceutical Manufacturing Projects
NEWARK, Del., June 8, 2021 — The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce funding for 10 new projects in technology, workforce development, and their Global Health Fund initiative, resulting from the Institute’s Project Call 4.1, and with a total value of approximately $4.6M.
NIIMBL eXperience Program Announces 17 Students for 2021 Cohort
CORRECTION 4/22/2021: Update to students’ names and associated institutions.
Newark, Del., April 20, 2021 – The National Institute for Manufacturing Biopharmaceuticals (NIIMBL) announced 17 students selected for their 2021 NIIMBL eXperience Program. The NIIMBL eXperience is offered to African American/Black, Latinx, and Native American college freshman and sophomores students from Historically Black Colleges and Universities (HBCUs) and NIIMBL member institutions and provides real-world insight into career options in the growing biopharmaceutical industry.
NIIMBL Welcomes Dr. Gene Schaefer as Senior Fellow
Newark, Del., April 13, 2021 – The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce that Dr. Gene Schaefer has joined the Institute as NIIMBL Senior Fellow, effective April 5, 2021. Dr. Schaefer joins NIIMBL with over 35 years of experience in the biopharmaceutical field ranging from early-stage process development to commercial product support for protein therapeutics.
ARP Response 2021
American Rescue Plan (ARP) Response
Submissions Due Friday, April 9, 2021 by 5:00 pm ET
Announced: March 30, 2021
NIIMBL Leads Joint Publication on End-to-End Process Intensification Program
The NIIMBL leadership along with colleagues from the government and the biopharma industry authored a recent publication in Biotechnology & Bioengineering describing NIIMBL’s ambitious 10-year collaborative program to invent, design, demonstrate, and support the commercialization of integrated biopharmaceutical manufacturing technology intended to transform the industry.
NIIMBL Welcomes Bradley Yops, NIIMBL Senior Counsel
NIIMBL is pleased to welcome Bradley Yops, who joins our team as NIIMBL Senior Counsel, effective immediately.
Brad brings extensive experience in technology transfer having served as the University of Delaware’s Director of Technology Transfer prior to becoming Assistant General Counsel in 2019. He is admitted to the bars of the Commonwealth of Pennsylvania, and the United States Patent & Trademark Office. Brad received his B.S. in Biology from Kansas State University, an M.S. in Pharmaceutical Chemistry and J.D. from the University of Kansas.
NIIMBL Expands the Possibilities of Careers in BioPharma for 13 College Students
With biologics making up about 40% of the global pipeline coupled with the rise in demand for cell and gene therapies, it is no secret the biopharma industry will need an influx of talent to meet its future workforce needs. This summer, 12 organizations had a chance to connect directly with 13 rising sophomores and juniors to begin building that talent pipeline during the virtual 2020 NIIMBL eXperience held from July 21-August 13.
NIIMBL Release 2019-2020 Annual Report
Download the March 2019 – February 2020 Annual Report here.
This year’s report highlights how our community of more than 150 members is advancing the biopharmaceutical industry by developing new technologies and strengthening the talent pipeline.
NIIMBL Announces Nine Project Recipients of $8.9M in Pandemic Response Efforts
NEWARK, DE. — Today, the National Institute for Innovation in Manufacturing Biopharmacueticals (NIIMBL) announces that they have identified nine projects to allocate approximately $8.9 million from the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) award received in May 2020 towards the support of the nation’s response to the COVID-19 pandemic.
NIIMBL is Awarded $8.9M from NIST for Pandemic Response
NEWARK, DE. — Today, the National Institute for Innovation in Biopharmaceutical Manufacturing (NIIMBL) announces that they have received $8.9 million from the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST). This award will fund high-impact projects that will support the nation’s response to the COVID-19 pandemic. The funding is part of the first round of funding made available to NIST through the Coronavirus Aid, Relief, and Economic Security (CARES) Act.